Serum S100A14 levels were positively correlated with CCL2 and CCL5 levels. Analyses of the GEO database showed that the increased expression levels of S100A14, CCL2, or CXCL5 in primary BC were a determinant of poor metastasis-free survival in BC patients, suggesting that targeting S100A14 may inhibit aberrant CCL2/CXCL5 signaling in metastatic BC [160]. This evidence concerns the gene S100A14 and breast cancer.